SCHEMBL1685204

SCHEMBL1685204

O=C1N=Cc2cc(-c3ccc(Nc4ccc(C(=O)N5CCOCC5)cc4)c4nccn34)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.43
MAPKAPK5 Q8IW41 5/20 0.43
BTK Q06187 3/20 0.43
JAK2 O60674 2/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
JAK3 P52333 1/20 0.41
CCNT1 O60563 1/20 0.40
CDK1 P06493 1/20 0.40
CDK4 P11802 1/20 0.40
CCNA2 P20248 1/20 0.40
CCND1 P24385 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
CCND3 P30281 1/20 0.40
CDK9 P50750 1/20 0.40
CDK3 Q00526 1/20 0.40
CDK6 Q00534 1/20 0.40
CDK5R1 Q15078 1/20 0.40
MAPK10 P53779 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1685148 0.88 HRH3 (0.38) RIPK1MAPKAPK5BTKCCNT1CDK1
SCHEMBL1685151 0.88 CCND1 (0.39) RIPK1MAPKAPK5BTKCCNT1CDK4
SCHEMBL1685127 0.88 MAPKAPK5 (0.55) MAPKAPK5MAPK10FYN
SCHEMBL1685173 0.87 MKNK1 (0.43) MKNK1MKNK2
SCHEMBL1685123 0.86 MAPKAPK2 (0.34) RIPK1MAPKAPK5BTKCCNT1CDK1
SCHEMBL1685207 0.85 MAPKAPK5 (0.60) RIPK1MAPKAPK5BTKJAK2JAK1
SCHEMBL12618756 0.85 MAPKAPK5 (0.58) RIPK1MAPKAPK5BTKJAK2JAK1
SCHEMBL3881243 0.84 CDK1 (0.39) JAK2JAK1CDK1CDK2MKNK1
SCHEMBL3868797 0.84 AURKA (0.49) MAPKAPK5CCNE1CDK2
SCHEMBL1685336 0.84 JAK1 (0.35) RIPK1JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 RIPK1 589/4885MAPKAPK5 19/4885BTK 1809/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 RIPK1 589/4885MAPKAPK5 19/4885BTK 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.